Ghidul pentru managementul hipertensiunii arteriale 2007 Grupul ...

More documents

Recommendations

Info

Revista Română de CardiologieVol. XXII, Nr. 3, 2007Ghidul pentru managementul hipertensiunii arteriale 2007Ghid al Societăţii Europene de Cardiologie734. Wing RR, Phelan S. Long-term weight loss maintenance. Am J ClinNutr 2005;82 (1 Suppl):222S-225S. RV.735. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, SevergniniB, Meani S, Magrini F, Zanchetti A. High prevalence of cardiacand extra-cardiac target organ damage in refractory hypertension. JHypertens 2001; 19:2063-2070. OS.736. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, NiroumandM, Leung RS, Bradley TD. High prevalence of unrecognized sleepapnoea in drug-resistant hypertension. J Hypertens 2001; 19:2271-2277. OS.737. Parati G, Ongaro G, Bonsignore MR, Glavina F, Di Rienzo M, ManciaG. Sleep apnoea and hypertension. Curr Opin Nephrol Hypertens2002; 11:201 214. RV.738. Narkiewicz K, Wolf J, Lopez-Jimenez F, Somers VK. Obstructive sleepapnea and hypertension. Curr Cardiol Rep 2005;7:435-440. RV.739. Baguet JP, Narkiewicz K, Mallion JM. Update on hypertension management:obstructive sleep apnea and hypertension. J Hypertens 2006;24:205-208. RV.740. Calhoun DA. Low-dose aldosterone blockade as a new treatmentparadigm for controlling resistant hypertension. J Clin Hypertens2007; 9(Suppl 1):19-24. RV.741. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, ZhaoQ, Pratt JH. Improvement in blood pressure with inhibition of theepithelial sodium channel in blacks with hypertension. Hypertension2005;46:481-487. RT.742. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in managementof resistant hypertension: a surveillance study. J Hypertens2007;25:891-894. OS.743. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-reninstatus in therapy-resistant hypertension: a clue to efficient treatment. JHypertens 2004; 22:2217-2226. OS.744. de Leeuw PW, Kroon AA, Scheffers I, Tordoir J, Schmidli, MohauptM, Allemann Y, Jordan J, Engeli S, Liebeskind U, Luft FC, Eckert S,Hansky B, Kieval R, Cody R, Rossing M, Irwin E, Peters T. Baroreflexhypertension therapy with a cronically implanted system: preliminaryefficacy and safety results from the rheos debut-ht study in patientswith resistant hypertension. J Hypertens 2006; 24(Suppl 4):S300.(abstract).745. Isles CG. Malignant hypertension and hypertensive encephalophaty.In: Swales JD editor. Textbook of Hypertension. London: BlackwellScientific Publications; 1994. pp.1233-1248. RV.746. Davis BA, Crook JE, Vestal RE, Oates JA. Prevalence of renovascularhypertension in patients with grade III or IV hypertensive retinopathy.N Engl JMed 1979;301:1273-1276. OS.747. Lip GY, Beevers M, Beevers G. The failure of malignant hypertensionto decline: a survey of 24 years’ experience in a multiracial populationin England. J Hypertens 1994;12:1297-1305. OS.748. Giese J. Acute hypertensive vascular disease, 2: Studies on vascularreaction patterns and permeability changes by means of vital microscopyand colloidal tracer technique. Acta Pathol Microbiol Scand1964;62:497-515. OS.749. Kincaid-Smith P, McMichael J, Murphy EA. The clinical cause andpathology of hypertension with papilloedema. Quart J Med 1958;27:117-154. OS.750. Isles CG, Liu KG, Boulton-Jones M, Cameron H, Lever AF, MurrayG, Robertson JWK. Factors influencing mortality in malignant hypertension.J Hypertens 1985;3(Suppl 3):405-407. OS.751. Lip GY, Beevers M, Beevers DG. Complications and survival of 315patients with malignant-phase hypertension. J Hypertens 1995; 13:915-924. OS.752. Gotto AM Jr. Review of primary and secondary prevention trials withlovastatin, pravastatin, and simvastatin. Am J Cardiol 2005;96:34F-38F. RV.753. Clearfield M. Statins and the primary prevention of cardiovascularevents. Curr Atheroscler Rep 2006;8:390-396. RV.754. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primaryprevention of cardiovascular diseases with statin therapy: ameta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-2313. MA.755. Gorelick PB, Schneck M, Berglund LF, Feinberg W, Goldstone J. Statusof lipids as a risk factor for stroke. Neuroepidemiology 1997;16:107-115. RV.756. Heart Protection Study Group. MRC/BHF Heart Protection Study ofcholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial. Lancet 2002;360:7-22. RT.757. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, CobbeSM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, MacfarlanePW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, SweeneyBJ, Twomey C, Westendorp RG. PROSPER study group. PROspectiveStudy of Pravastatin in the Elderly at Risk. Pravastatin in elderlyindividuals at risk of vascular disease (PROSPER): a randomisedcontrolled trial. Lancet 2002;360:1623-1630. RT.758. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, HennericiM, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM,Zivin JA. Stroke Prevention by Aggressive Reduction in CholesterolLevels (SPARCL) Investigators. High-dose atorvastatin after stroke ortransient ischemic attack. N Engl J Med 2006;355:549-559. RT.759. The ALLHAT Officers, Coordinators for the ALLHAT CollaborativeResearch Group. Major outcomes in moderately hypercholesterolemic,hypertensive patients randomized to pravastatin vs usual care. TheAntihypertensive and Lipid-Lowering Treatment to Prevent HeartAttack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007. RT.760. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, CaulfieldM, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J,Nieminen M, O’Brien E, Ostergren J. ASCOT investigators. The preventionof coronary events and stroke with atorvastatin in hypertensivesubjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 2003;361:1149-1158. RT.761. Borghi C, Dormi A, Veronesi M, Immordino V, Ambrosioni E. Useof lipid-lowering drugs and blood pressure control in patients witharterial hypertension. J Clin Hypertens 2002;4:277-285. RV.762. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, BergmanAJ, Alton KB. Ezetimibe: a review of its metabolism pharmacokineticsdrug interactions. Clin Pharmacokinet 2005;44:467-494. RV.763. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysisof randomised trials of antiplatelet therapy for prevention of death,myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. MA.764. Zanchetti A, Hansson L, Dahlof B, Julius S, Menard J, Warnold I,Wedel H. Benefit and harm of low-dose aspirin in well-treated hypertensivesat different baseline cardiovascular risk. J Hypertens 2002;20:2301-2307. CT.765. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L,Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrelcompared with clopidogrel alone after recent ischaemic strokeor transient ischaemic attack in high-risk patients (MATCH): randomised,double-blind, placebo-controlled trial. Lancet 2004;364:331-337. RT.766. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE,Hennekens CH, Buring JE. A randomized trial of low-dose aspirin inthe primary prevention of cardiovascular disease in women. N Engl JMed 2005;352:1293-1304. RT.767. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primaryprevention of cardiovascular events: a summary of the evidencefor the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-172. MA.768. Wald NJ, Law MR. A strategy to reduce cardiovascular disease bymore than 80%. BMJ 2003;326:1419. RV.769. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE.Aspirin for primary prevention of coronary heart disease: safety andabsolute benefit related to coronary risk derived from meta-analysisof randomised trials. Heart 2001;85:265-271. MA.770. Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, WarnoldI, Wedel H. Low-dose aspirin does not interfere with the blood pressure-loweringeffects of antihypertensive therapy. J Hypertens 2002;20:1015-1022. RT.771. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortalityfrom coronary heart disease in subjects with type 2 diabetes and in
Ghidul pentru managementul hipertensiunii arteriale 2007Ghid al Societăţii Europene de Cardiologienon-diabetic subjects with and without prior myocardial infarction.N Engl J Med 1998;339:229-234. OS.772. Stamler J, VaccaroO, Neaton JD, Wentworth D. Diabetes other riskfactors12-yr cardiovascular mortality for men screened in the MultipleRisk Factor Intervention Trial. Diabetes Care 1993;16:434-444.OS.773. Knowler WC, Sartor G, Melander A, Schersten B. Glucose toleranceand mortality, including a substudy of tolbutamide treatment.Diabetologia 1997;40:680-686. OS.774. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertensionand antihypertensive therapy as risk factors for type 2 diabetesmellitus. Atherosclerosis Risk in Communities Study. N Engl J Med2000; 342:905-912. OS.775. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventionaltreatment and risk of complications in patients with type 2diabetes (UKPDS 33). Lancet 1998;352:837-853. RT.776. Chiasson JL, Josse RG, Gomis R, Hanefeld M, KarasikA, LaaksoM. Acarbose treatment and the risk of cardiovascular disease andhyper tension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290:486-494. RT.777. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.Multi-factorial intervention and cardiovascular disease in patientswith type 2 diabetes. N Engl J Med 2003;348:383-393. RT.778. The Diabetes Control, Complications Trial Research Group. The effectof intensive treatment of diabetes on the development and progressionof long-term complications in insulin-dependent diabetes mellitus. NEngl JMed 1993;329:977-986. RT.779. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM,Orchard TJ, Raskin P, Zinman B. Diabetes Control ComplicationsTrial/Epidemiology of Diabetes Interventions Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovasculardisease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653. CT.780. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, EschwegeE. High blood glucose concentration is a risk factor for mortalityin middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki PolicemenStudy. Diabetes Care 1998; 21:360-367. OS.781. European Diabetes Policy Group 1999. A desktop guide to type 2diabetes mellitus. Diabetes Med 1999;16:716-730. GL.782. ADVANCE trial study group Rationale, design of the ADVANCEstudy: a randomised trial of blood pressure lowering, intensive glucosecontrol in high-risk individuals with type 2 diabetes mellitus.Action in Diabetes and Vascular Disease: PreterAx and DiamicroNMo dified-Release Controlled Evaluation. J Hypertens 2001; 19(Suppl):S21-S28. RT.783. Campos C, Segura J, Rodicio JL. Investigations in secondary hypertension:renal disease. In: Zanchetti A, Hansson L, Rodicio JL. editors,Hypertension. London: McGraw Hill International; 2001. pp. 119-126.RV.784. Keane WF, Eknoyan G. Proteinuria albuminuria risk assessment detectionelimination (PARADE): a position paper of the National KidneyFoundation. Am J Kidney Dis 1999;33:1004-1010. GL.785. Koler H, Wandel E, Brunck B. Acanthocyturia - a characteristic markerfor glomerular bleeding. Kidney Int 1991;40:115-120. OS.786. Elliott WJ. Secondary hypertension: renovascular hypertension. In:Blackh & Elliott WG (eds). Hypertension: a Companion to Braunwald’sHeart Disease. Saunders Elsevier, 2007, pp. 93-105. RV.787. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344:431-442. RV.788. Krumme W, Blum U, Schwertfeger E, Fliigel P, Hollstin F, SchollmeyerP, Rump LC. Diagnosis of renovascular disease by intra-extrarenalDoppler scanning. Kidney Int 1996;50:1288-1292. OS.789. Vasbinder BGC, Nelemans PJ, Kessels AGH, Kroon AA, De LeeuwPW, van Engelshoven JMA. Diagnostic tests for renal artery stenosisin patients suspected of having renovascular hypertension: a metaanalysis.Ann Intern Med 2001; 135:401-411. MA.790. Bruce GH. Intervention for renal artery stenosis: endovascular andsurgical roles. J Hypertens 2005;23(Suppl 3):S23-S29. RV.Revista Română de CardiologieVol. XXII, Nr. 3, 2007791. Aurell M, Jensen G. Treatment of renovascular hypertension. Nephron1997;75:373-383. RV.792. Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcomeof angioplasty in atherosclerotic renal artery stenosis: a randomizedtrial. Essai Multicentrique Medicaments vs Angioplastie (EMMA)Study Group. Hypertension 1998;31:823-829. RT.793. Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, IslesCG, Loose H, Main J, Padfield P, Russell IT, Walker B, Watson M,Wilkinson R. Randomised comparison of percutaneous angioplastyvs continued medical therapy for hypertensive patients with atheromatousrenal artery stenosis. Scottish and Newcastle Renal ArteryStenosis Collaborative Group. J Hum Hypertens 1998;12:329-335.OS.794. van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J,Postma CT, Dees A, Woittiez AJ, Bartelink AK, Man in 0tVeld AJ,Schalekamp MA. The effect of balloon angioplasty on hypertensionin atherosclerotic renal-artery stenosis. Dutch Renal Artery StenosisInter vention Cooperative Study Group. N Engl J Med 2000;342:1007-1014. OS.795. Nordmann AJ, Woo K, Parkes R, Logan AG. Balloon angioplasty ormedical therapy for hypertensive patients with atherosclerotic renalartery stenosis? A meta-analysis of randomized controlled trials. AmJ Med 2003;114:44-50. MA.796. Reisch N, Peczkowska M, Januszewicz A, Neumann HP. Pheochromocytoma:presentation diagnosis treatment. J Hypertens 2006;24:2331-2339. RV.797. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemicaltests for pheochromocytoma: measurement of fractionatedplasma metanephrines compared with the combination of 24-hoururinary metanephrines and catecholamines. J Clin Endocrinol Metab2003;88:553-558. OS.798. Bravo EL. Evolving concepts in the pathophysiology diagnosis treatmentof pheochromocytoma. Endocrine Rev 1994; 15:356-368. RV.799. Goldstein DS, Eisenhofer G, Flynn JA, Wand G, Pacak K. Diagnosisand localization of pheochromocytoma. Hypertension 2004;43:907-910. RV.800. Sjoberg RJ, Simcic KJ, Kidd GS. The clonidine suppression test forpheochromocytoma. A review of its utility and pitfalls. Arch InternMed 1992;152:1193-1197. RV.801. Ilias I, Pacak K. Current approaches and recommended algorithm forthe diagnostic localization of pheochromocytoma. J Clin EndocrinolMetab 2004;89:479-491. RV.802. Gimm O, Koch CA, Januszewicz A, Opocher G, Neumann HP. Thegene tic basis of pheochromocytoma. Front Horm Res 2004;31:45-60.RV.803. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C,Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F,Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, PorteriE, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, ManteroF. PAPY Study Investigators. A prospective study of the prevalenceof pri mary aldosteronism in 1125 hypertensive patients. J Am CollCardiol 2006;48:2293-2300. OS.804. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G,Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients. J Hypertens 2003;21:2149-2157. OS.805. Bravo EL, Tarazi RC, Dustan HP, Fouad FM, Textor SC, Gifford RW,Vidt DG. The changing clinical spectrum of primary aldosteronism.Am J Med 1983;74:641-651. RV.806. Ganguly A. Primary aldosteronism. N Engl J Med 1998;339:1828-1834. RV.807. Kaplan NM. The current epidemic of primary aldosteronism: causesand consequences. J Hypertens 2004;22:863-869. RV.808. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. Highincidence of primary aldosteronism in 199 patients referred withhyper tension. Clin Exp Pharmacol Physiol 1994;21:315-318. OS.809. Lins PE, Adamson U. Plasma aldosterone-plasma renin activity ratio.A simple test to identify patients with primary aldosteronism. ActaEndocrinol 1986;113:564-569. OS.
Page 3 and 4:
Vol. XXII, Nr. 3, 2007EDITORIALARTI
Page 5 and 6:
CONSILIUL DE CONDUCERE ALSOCIETĂŢ
Page 7 and 8:
Revista Română de Cardiologie | V
Page 9 and 10:
Page 11 and 12:
C. Zara şi col.Stenoza subaortică
Page 13 and 14:
Revista Română de CardiologieVol.
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
S. Kontogeorgos şi col.Testul de e
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
M. Rugină şi col.Incidentalom sup
Page 31 and 32:
M. Rugină şi col.Incidentalom sup
Page 33 and 34:
Page 35 and 36:
Actualităţi în cardiologieameric
Page 37 and 38:
Actualităţi în cardiologiepacien
Page 39 and 40:
Page 41 and 42:
Ghidul pentru managementul hiperten
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82: Ghidul pentru managementul hiperten
Page 131: Ghidul pentru managementul hiperten
Page 135: Revista Română de Cardiologie | V
show all

Ghidul pentru managementul hipertensiunii arteriale 2007 Grupul ...

Create successful ePaper yourself

Delete template?

Save as template?